Inovio Pharmaceuticals (INO) announced early Monday that regulators forced it to hold off on the start of its planned Phase 2/3 testing of its Covid-19 vaccine candidate, sending INO stock crashing early.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,